Back

Lipopolysaccharide-nuclear factor-kappa B pathway and lipoprotein apheresis effects in patients with familial hypercholesterolemia and coronary artery disease

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Lipids Lipids ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Chuanjue Cui

Beijing (China)

14 More presentations in this session

Presentation thumbnail
Patient characteristics and treatment patterns in patients on lipid-lowering therapies following an acute coronary syndrome in France
Professor E. Bruckert (Paris, FR)
Abstract Slides
Presentation thumbnail
What is the most important residual risk after achievement of appropriate low-density lipoprotein cholesterol lowering therapy in secondary prevention of Japanese patients?
Doctor A. Endo (Izumo, JP)
Abstract
Presentation thumbnail
Association of adherence and treatment intensity of lipid-lowering therapy with cardiovascular outcomes and all-cause mortality in very high-risk patients in Germany
Professor I. Ahrens (Cologne, DE)
Abstract
Presentation thumbnail
Relative fat mass (RFM) is a better predictor of dyslipidemia and metabolic syndrome than body mass index (BMI).
Doctor O. Kobo (Hadera, IL)
Abstract Slides
Presentation thumbnail
Low levels of low density lipoprotein cholesterol and cardiovascular, cancer and all-cause mortality outcomes
Professor K. Sung (Seoul, KR)
Abstract

Access the full session

Session thumbnail
Poster Session 1 - Lipids

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Webinar
Lipoprotein(a): a modifiable risk factor of atherosclerotic cardiovascular disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources